ArticleEuropean journal of nuclear medicine and molecular imaging2026
Comparative theranostic efficacy of
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
purposeMesothelin (MSLN), a 40 kDa glycoprotein normally confined to mesothelial cells, is overexpressed in several malignancies, including triple-negative breast cancer (TNBC). The anti-mesothelin single-domain antibody (sdAb, or “nanobody®”) DOTA-A1K2, previously validated for positron emission tomography (PET) imaging using site-specific 68Ga radiolabeling, may also serve as a radio-theranostic agent when labeled with 177Lu. Moreover, 161Tb has recently been proposed as an alternative to 177Lu that might provide additional efficacy due to the emission of Auger electrons. The aim of this study was to evaluate in vitro and in vivo the therapeutic effect of [177Lu]Lu-DOTA-A1K2 and [161Tb]Tb-DOTA-A1K2.
methodsBiodistribution was assessed in mice from 1 to 168 h post-injection. Therapeutic efficacy was tested using MDA-MB-231 TNBC cells transfected or not with MSLN. Clonogenic assays were performed after 24 h incubation with either radiotracer. In vivo, efficacy was evaluated over 9 weeks after a single intravenous injection of 2, 5, 10, or 20 MBq.
resultsDOTA-A1K2 was successfully radiolabeled with both isotopes with RCP > 95%. In vitro, [161Tb]Tb-DOTA-A1K2 was significantly more potent than [177Lu]Lu-DOTA-A1K2 in inhibiting colony formation (p < 0.01). In vivo in mice, the radiotracers exhibited similar biodistribution profiles. The administration of 5, 10 or 20 MBq of either [177Lu]Lu-DOTA-A1K2 or [161Tb]Tb-DOTA-A1K2 inhibited tumor growth compared to controls (p < 0.01 vs. vehicle), while no effect was observed at 2 MBq (p = NS). However, no differences in efficacy were observed between the two isotopes at any dose.
conclusionsThis work provides the first sdAb-based theranostic approach targeting mesothelin-positive tumors. In vivo in mice, both [177Lu]Lu-DOTA-A1K2 and [161Tb]Tb-DOTA-A1K2 accumulated in tumors. In vivo efficacy was found to be comparable, despite the superior in vitro efficacy of 161Tb. Further studies are warranted to clarify this discrepancy, which could potentially result from mesothelin shedding that prevents Auger electrons from reaching tumor cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.